Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.

ABSTRACT:

Background

There are limited treatment options for unresectable recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Vascular endothelial growth factor is of significant interest for targeted therapy in R/M HNSCC because of its central role in tumorigenesis and immunosuppression. Axitinib is a potent inhibitor of vascular endothelial growth factor receptor (VEGFR) 1 , VEGFR2, VEGFR3, platelet-derived growth factor receptor, as well as c-kit and offers such an approach.

Methods

This article reports the results of a phase 2 trial evaluating axitinib in R/M HNSCC according to the Choi criteria for radiographic response assessment. The primary endpoint of this trial was 6-month overall survival.

Results

Twenty-nine patients were enrolled, and 28 we

SUBMITTER: Swiecicki PL 

PROVIDER: S-EPMC10127531 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature